Greta Garassini

  • Citations Per Year
Learn More
No standard salvage chemotherapy has been identified for metastatic pancreatic adenocarcinoma (mPA), and there is an urgent need for active agents against this disease. This phase II trial explored the activity of trabectedin in mPA progressing after gemcitabine-based first-line chemotherapy. Patients with gemcitabine-resistant disease received trabectedin(More)